Urgent Work-up for Androgen-Secreting Tumor
This patient requires immediate imaging with pelvic ultrasound and measurement of DHEAS to rule out an androgen-secreting tumor, as testosterone levels >200 ng/dL (approximately 7 nmol/L) with suppressed gonadotropins strongly suggest either an ovarian tumor or ovarian hyperthecosis rather than PCOS.
Critical Clinical Context
The combination of markedly elevated testosterone (573 ng/dL is roughly 20 nmol/L, which is 10-fold above normal female range) with suppressed LH and FSH is a red flag pattern that differs fundamentally from PCOS, where LH is typically elevated or normal. This hormonal profile indicates autonomous androgen production that is suppressing the hypothalamic-pituitary axis.
Immediate Diagnostic Work-up
Essential First-Line Tests 1, 2:
- DHEAS measurement: If >600 µg/dL (16,000 nmol/L), this indicates adrenal source and requires abdominal CT immediately 2
- Pelvic ultrasound: To detect ovarian masses (even small tumors can produce massive androgen excess) 1
- Prolactin level: To exclude hyperprolactinemia 1
- 17-hydroxyprogesterone: To exclude non-classic congenital adrenal hyperplasia 1
Critical Physical Examination Findings to Document:
- Signs of virilization: Clitoromegaly, increased muscularity, deepening voice, male pattern baldness 1
- Rapid progression: Timeline of symptom onset (sudden onset suggests tumor) 1
- Palpable masses: Abdominal or pelvic examination 1
- Acanthosis nigricans: Suggests insulin resistance 1
Differential Diagnosis Priority
1. Androgen-Secreting Ovarian Tumor (Most Concerning)
- Testosterone >200 ng/dL makes tumor highly likely 1
- Can be small and difficult to detect on imaging 3, 4
- Includes Leydig cell tumors, steroid cell tumors 3, 4
- Malignant in 25-43% of cases 3
2. Ovarian Hyperthecosis
- Severe hyperandrogenism with suppressed gonadotropins 5, 6
- More common in postmenopausal women but can occur in 40s 6
- Associated with insulin resistance 2
- Benign but requires treatment
3. PCOS (Less Likely Given This Profile)
- Would typically show elevated or normal LH, not suppressed 1
- Testosterone elevation usually <2-fold above normal 1
- This patient's 10-fold elevation argues against PCOS
Diagnostic Confirmation Strategy
If initial imaging is negative but testosterone remains markedly elevated:
GnRH Antagonist Suppression Test 5, 4, 6:
- Administer cetrorelix or degarelix (GnRH antagonist)
- If testosterone suppresses: Confirms ovarian source (hyperthecosis or tumor)
- If testosterone does NOT suppress: Suggests adrenal source or autonomous tumor
- This test can be both diagnostic and temporarily therapeutic 5, 4
Advanced Imaging if Initial Studies Negative:
- Ovarian and adrenal vein sampling with multisteroid profiling by LC-MS/MS 5
- This identifies the exact source when imaging fails to localize
Common Pitfalls to Avoid
Laboratory Interference: With testosterone this high, consider diethyl-ether extraction prior to immunoassay to rule out assay interference 3. However, given suppressed gonadotropins, this is likely real hyperandrogenism.
Missing Small Tumors: Androgen-secreting tumors can be as small as 6mm and still produce massive testosterone elevation 4. Repeat imaging or consider MRI if ultrasound negative.
Assuming PCOS: The suppressed LH/FSH pattern is not consistent with PCOS and should prompt immediate tumor work-up 1.
Medication History: Verify no exogenous androgen use (anabolic steroids, testosterone supplementation) or valproic acid 1.
Management Approach
If Tumor Identified:
- Surgical excision (salpingo-oophorectomy for ovarian source) 4, 6
- Testosterone normalizes within 24-48 hours post-operatively 3
If Ovarian Hyperthecosis Confirmed:
- GnRH antagonist therapy (degarelix) can provide long-term suppression without surgery 5
- Alternative: Bilateral salpingo-oophorectomy 6
If All Work-up Negative:
- Consider repeat imaging in 3-6 months
- Trial of GnRH antagonist both diagnostically and therapeutically 5, 4
Timeline for Action
This requires urgent (within 1-2 weeks) rather than emergent evaluation, but should not be delayed. The risk of malignancy and the degree of androgen excess warrant prompt investigation 1, 3.